ARCHIVES

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML

This article is from The Cancer Letter archive.

Vol. 30 No. 12 | December 28, 2007

Download PDF Visit The Full Archive

Related Articles

UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status

November 28, 1975

Letter to the Editor: Colleagues describe Bunn As Leader, Patient Advocate

January 12, 1996

In Brief: Fidler Wins BMS Cancer Research Award; Thomas Cech To Head Howard Hughs Inst.

April 2, 1999

ACS President & COO Resigns Unexpectedly; Was Seen as Contender for CEO Position

December 19, 2014

PDQ Now Offers CME Credit to Physician Users

July 3, 1987

FDA Grants Priority Review To Two Drugs in NSCLC

February 22, 2013